Metformin Medical Valley

Metformin, the active ingredient in Metformin Medical Valley, is a biguanide presented as an oral tablet for oral use. It lowers elevated blood glucose levels and is used primarily in adults with type 2 diabetes mellitus, and helps improve insulin sensitivity as part of a comprehensive glycemic control regimen.

GNH USA supplies Metformin Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across all regions.

Metformin is indicated for conditions related to impaired glucose regulation and is a cornerstone therapy in the management of type 2 diabetes. - Type 2 diabetes mellitus: improves glycemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when combined with lifestyle modification. - Gestational diabetes mellitus (when insulin is not required): helps maintain target blood glucose levels during pregnancy.

Metformin may cause a range of adverse reactions, most of which are mild and transient, while rare events can be serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and diarrhea. - Metallic taste: transient alteration in taste perception. - Decreased appetite: reduced food intake leading to mild weight loss.

Serious or Rare Side Effects: - Lactic acidosis: potentially life‑threatening metabolic acidosis. - Vitamin B12 deficiency: may develop with long‑term therapy. - Hepatotoxicity: rare liver enzyme elevations. - Severe skin reactions: such as Stevens‑Johnson syndrome.

When prescribing Metformin, clinicians should consider several precautionary measures to ensure patient safety. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic disease: avoid use in patients with significant liver impairment. - Cardiovascular status: monitor for signs of heart failure, especially in the elderly. - Concomitant medications: review for drugs that may increase risk of lactic acidosis. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Metformin's pharmacokinetic profile leads to several clinically relevant drug interactions.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol excess: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Diuretics: can reduce renal clearance of metformin. - Beta‑blockers: may mask hypoglycemia symptoms.